GHK-Cu vs PEA (Palmitoylethanolamide)

Overview

GHK-Cu and PEA (Palmitoylethanolamide) are both pain management peptides, but they differ in mechanism, dosing, and regulatory status.

This page compares GHK-Cu and PEA (Palmitoylethanolamide) across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

Key differences

Primary use. GHK-Cu is categorised under Pain Management, while PEA (Palmitoylethanolamide) falls under Pain Management. Because they target a similar goal, they are common alternatives to weigh against each other.

Regulatory status. GHK-Cu: not FDA-approved; compounding permitted with a prescription as of April 2026. PEA (Palmitoylethanolamide): not FDA-approved; treated as a research compound.

Dosing. GHK-Cu is typically dosed at 1-3 mg (daily). PEA (Palmitoylethanolamide) is typically dosed at 300-600 mg (twice daily).

Can you stack them?

Some protocols combine peptides, but stacking GHK-Cu and PEA (Palmitoylethanolamide) has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between GHK-Cu and PEA (Palmitoylethanolamide)?

GHK-Cu and PEA (Palmitoylethanolamide) are both pain management peptides, but they differ in mechanism, dosing, and regulatory status. GHK-Cu is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas PEA (Palmitoylethanolamide) is not FDA-approved; generally classified as a research compound.

What is GHK-Cu used for?

Anti-inflammatory tissue repair.

What is PEA (Palmitoylethanolamide) used for?

Natural pain modulator.

Can you take GHK-Cu and PEA (Palmitoylethanolamide) together?

Some users combine peptides within a single protocol, but stacking GHK-Cu and PEA (Palmitoylethanolamide) has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.

Is GHK-Cu or PEA (Palmitoylethanolamide) FDA-approved?

GHK-Cu is not FDA-approved; compounding permitted with a prescription (as of April 2026). PEA (Palmitoylethanolamide) is not FDA-approved; generally classified as a research compound.